{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:41:06Z","timestamp":1784551266969,"version":"3.55.0"},"reference-count":20,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["NCT02058160"],"award-info":[{"award-number":["NCT02058160"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,10]]},"abstract":"\n Aims<\/jats:title>\n \n To assess the impact of baseline characteristics on clinical outcomes in the\n LixiLan\u2010L<\/jats:styled-content>\n trial, a randomized open\u2010label trial designed to evaluate the efficacy and safety of\n iGlarLixi<\/jats:styled-content>\n , a novel fixed\u2010ratio combination of insulin glargine 100\u2009U (\n iGlar<\/jats:styled-content>\n ) plus lixisenatide, in comparison with\n iGlar<\/jats:styled-content>\n over 30\u2009weeks in a population of patients with type 2 diabetes mellitus (\n T2DM<\/jats:styled-content>\n ) inadequately controlled on a previous regimen of basal insulin alone or in combination with 1 or 2 oral glucose\u2010lowering drugs.\n <\/jats:p>\n <\/jats:sec>\n \n \n Materials and\n M<\/jats:styled-content>\n ethods\n <\/jats:title>\n \n In this exploratory analysis of\n LixiLan\u2010L<\/jats:styled-content>\n (\n \n N<\/jats:styled-content>\n <\/jats:italic>\n \u2009=\u2009736), efficacy outcomes were assessed within population subgroups derived from the following baseline characteristics: glycated haemoglobin [\n HbA1c<\/jats:styled-content>\n ; <8%, \u22658% (<64, \u226564\u2009mmol\/mol)]; duration of\n T2DM<\/jats:styled-content>\n (<10, \u226510\u2009years); body mass index (<30, \u226530\u2009kg\/m\n 2<\/jats:sup>\n ). Furthermore, the incidence of symptomatic hypoglycaemia with plasma glucose \u22643.9\u2009mmol\/L (\u226470\u2009mg\/\n dL<\/jats:styled-content>\n ) was also analysed according to the same subgroups.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Compared with the\n iGlar<\/jats:styled-content>\n treatment group, patients treated with\n iGlarLixi<\/jats:styled-content>\n showed consistently greater reductions in\n HbA1c<\/jats:styled-content>\n during the treatment period, with higher percentages of patients achieving the\n HbA1c<\/jats:styled-content>\n target level of <7% (<53\u2009mmol\/mol) in all of the subpopulations tested (\n \n P<\/jats:styled-content>\n <\/jats:italic>\n \u2009<\u2009.0001 for all), having consistent mitigation of body weight gain and with no major differences in the incidence of hypoglycaemia.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n iGlarLixi<\/jats:styled-content>\n consistently improved glycaemic control compared with\n iGlar<\/jats:styled-content>\n in all baseline characteristic subgroups of patients with\n T2DM<\/jats:styled-content>\n inadequately controlled with insulin, including difficult\u2010to\u2010treat subgroups of patients with long duration of diabetes, obesity and high\n HbA1c<\/jats:styled-content>\n .\n <\/jats:p>\n \n Clinical trial number:\n NCT02058160<\/jats:styled-content>\n (\n clinicaltrials.gov<\/jats:ext-link>\n ).\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12961","type":"journal-article","created":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T22:33:24Z","timestamp":1491518004000},"page":"1408-1415","source":"Crossref","is-referenced-by-count":27,"title":["Consistent findings in glycaemic control, body weight and hypoglycaemia with\n iGlarLixi<\/scp>\n (insulin glargine\/lixisenatide titratable fixed\u2010ratio combination) vs insulin glargine across baseline\n HbA1c<\/scp>\n ,\n BMI<\/scp>\n and diabetes duration categories in the\n LixiLan\u2010L<\/scp>\n trial"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3056-0047","authenticated-orcid":false,"given":"Carol","family":"Wysham","sequence":"first","affiliation":[{"name":"Rockwood Clinic Spokane Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo C.","family":"Bonadonna","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolic Diseases, Department of Clinical and Experimental Medicine University of Parma and AOU of Parma Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita R.","family":"Aroda","sequence":"additional","affiliation":[{"name":"Medstar Health Research Institute Hyattsville Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Puig Domingo","sequence":"additional","affiliation":[{"name":"Germans Trias i Pujol Research Institute and Hospital Universitat Aut\u00f2noma de Barcelona Barcelona Spain"},{"name":"CIBERER and CIBERDEM Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kapitza","sequence":"additional","affiliation":[{"name":"Profil Institute Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Stager","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Yu","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Niemoeller","sequence":"additional","affiliation":[{"name":"Sanofi Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Souhami","sequence":"additional","affiliation":[{"name":"Sanofi Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Bergenstal","sequence":"additional","affiliation":[{"name":"International Diabetes Center Park Nicollet Health Services Minneapolis Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the LixiLan\u2010L trial investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"issue":"1","key":"e_1_2_6_2_1","first-page":"S1","article-title":"Standards of medical care in diabetes \u2013 2016","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.733"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12290"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2013.04.001"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1984"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2462"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2454"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0785"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1252"},{"issue":"1","key":"e_1_2_6_14_1","first-page":"938\u2010P","article-title":"Impact of BMI on HbA1c reduction in response to IDegLira in subjects with type 2 diabetes (T2D) uncontrolled on SU, GLP\u20101RA or insuline glargine: analyses from completed phase 3 b trials","volume":"65","author":"Harris S","year":"2016","journal-title":"Diabetes"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1434"},{"issue":"1","key":"e_1_2_6_16_1","first-page":"925\u2010P","article-title":"IDegLira is efficacious across baseline HbA1c categories in subjects with type 2 diabetes uncontrolled on SU, GLP\u20101RA or insulin glargine: analyses from completed phase 3b trials","volume":"65","author":"Sorli C","year":"2016","journal-title":"Diabetes"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12129"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2006"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1935"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01618.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2541"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12961","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:36:33Z","timestamp":1761885393000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/dom.12961"],"URL":"https:\/\/doi.org\/10.1111\/dom.12961","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]}}}